With a long history of development and manufacturing of generic products, Pharmathen has emerged as one of the largest generic development companies in Europe with a development pipeline of ten generic molecules a year.
Today, Pharmathen's in-house development products are registered in all major EU markets and licensed out to major pharmaceutical companies in Europe, Canada, Australia, South Africa and the United States. Our competitive edge is characterized by cost efficient development and production, creative marketing and added value customer service